Health and Human Services News and Research

RSS

Angioblast Systems receives $1.2 million in grants under QTDP program

Regenerative medicine company, Mesoblast Limited, today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

Maine requests exemption from federal law, Southern Calif. hospital pays $5 million to resolve charges of false Medicare claims

Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The

8 Nov 2010

ST Cardio Technologies receives $244,479 QTDP Program grant to develop Z6 Cardiac Stimulator

ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.

8 Nov 2010

Rcopia-MU certified as EHR Module by CCHIT

DrFirst announced today that Rcopia-MU, Version 3, is 2011/2012 compliant and was certified as an EHR Module on November 4, 2010, by the Certification Commission for Health Information Technology (CCHIT), an ONC-ATCB, in accordance with the applicable eligible provider certification criteria adopted by the Secretary of Health and Human Services.

8 Nov 2010

Tomophase to commercialize OCT Imaging System for pulmonary applications with QTDP award

Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced that it has received an award from the Departments of the Treasury and Health and Human Services for the Qualifying Therapeutic Discovery Project (QTDP.)

8 Nov 2010

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project program.

8 Nov 2010

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.

8 Nov 2010

Illinois life sciences receives $14.5 million in grants under QTDP program

At least 59 Illinois life sciences companies were awarded over $14.5 million in grants or tax credits under the Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

Stereotaxis receives $1.5 million in grants under QTDP program

Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

Achillion receives $2.0 million in eight federal grants under QTDP program

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that is has been awarded approximately $2.0 million in eight federal grants under the Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Antigenics awarded $424,720 grant under QTDP program

Antigenics Inc. today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon® adjuvant.

4 Nov 2010

NextGen Inpatient Clinicals version 2.4 earns CCHIT Certified 2011 Inpatient EHR designation

NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced that NextGen® Inpatient Clinicals version 2.4 has earned designation as a premarket conditionally CCHIT Certified® 2011 Inpatient EHR.

4 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

HRSA awards grants to develop new approaches for organ donation

The Health Resources and Services Administration (HRSA) has announced more than $2.2 million in grants to help identify effective strategies for increasing organ donation.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying Therapeutic Discovery Project (QTDP) grants program to advance the development of the company's three programs, REG1, REG2 and REG3.

4 Nov 2010

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

4 Nov 2010

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.

4 Nov 2010

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

Health and Human Services News and Research

Angioblast Systems receives $1.2 million in grants under QTDP program

Maine requests exemption from federal law, Southern Calif. hospital pays $5 million to resolve charges of false Medicare claims

ST Cardio Technologies receives $244,479 QTDP Program grant to develop Z6 Cardiac Stimulator

Rcopia-MU certified as EHR Module by CCHIT

Tomophase to commercialize OCT Imaging System for pulmonary applications with QTDP award

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

Illinois life sciences receives $14.5 million in grants under QTDP program

Stereotaxis receives $1.5 million in grants under QTDP program

NWBT receives $490,000 in two grants under QTDP program

Achillion receives $2.0 million in eight federal grants under QTDP program

Antigenics awarded $424,720 grant under QTDP program

NextGen Inpatient Clinicals version 2.4 earns CCHIT Certified 2011 Inpatient EHR designation

Aestus receives $244,000 grant from QTDP program

HRSA awards grants to develop new approaches for organ donation

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News